Meet the Start-ups

Jord Stam | CEO | Clear2Cure

Jord Stam has built a career spanning over three decades in biomedical research, antibody technology, and entrepreneurship. He started with yeast in biotechnology before earning his PhD at the Dutch Cancer Institute, studying tumour cell metastasis. With a strong interest in therapeutics, he explored cancer, aging, and blood purification, using small llama antibodies.

In response to a Bill & Melinda Gates Foundation call for novel HIV treatments, he developed a method using bispecific llama antibodies for targeted protein degradation. Building on this concept, he founded Clear2Cure BV in 2023 to develop universal strategies for tackling viral threats, as well as broader therapeutic applications beyond viruses.

Jord enjoys shifting focus from scientific scrutiny to developing therapies that truly work.

Clear2Cure

Clear2Cure is a biotech spin-off from Utrecht University developing Clearbodies®, a novel class of antibody-derived therapeutics that actively degrade disease-causing molecules. Instead of just blocking targets, Clearbodies® capture harmful proteins and direct them to abundant membrane proteins like EGFR, leading to their breakdown in lysosomes.

This immune-independent approach leverages small, stable nanobodies (VHHs), enabling easier production, lower immunogenicity, and broad applications—particularly against pathogens and toxic proteins that conventional antibodies and traditional drugs struggle with.

A patent for Clearbodies® was filed in 2022, and Clear2Cure B.V. was incorporated in 2023 to advance this technology. The company is particularly interested in viruses and IL-6 and is open to partnerships on other promising targets, including toxins, cytokines, autoantibodies, and neurodegenerative protein aggregation diseases.